Takhzyro Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The takhzyro market research report is one of a series of new reports that provides takhzyro market statistics, including the takhzyro industry global market size, regional shares, competitors with the takhzyro market share, detailed takhzyro market segments, market trends, and opportunities, and any further data you may need to thrive in the takhzyro industry. This takhzyro market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to shifting towards personalized treatments in healthcare, an aging population, shifting towards prophylactic treatments, the prevalence of hereditary angioedema (HAE), and the increasing use of telemedicine. Major trends in the forecast period include digital and AI integration, adoption of precision medicine, advanced drug delivery systems, technological advancements, and integration of digital health technologies.

The takhzyro market is expected to grow as the prevalence of hereditary angioedema (HAE) continues to rise. HAE is a rare genetic condition characterized by recurrent, severe swelling in various body parts, often affecting the airway, and can even be life-threatening. The increase in HAE cases can be attributed to better awareness, advancements in genetic testing, and the identification of spontaneous mutations in the C1 inhibitor gene, along with environmental triggers. Takhzyro (lanadelumab) is used to prevent HAE attacks by inhibiting kallikrein, reducing bradykinin levels, and lessening the frequency and severity of swelling episodes. According to Rare Disease Advisor, in June 2022, HAE affects approximately 1 in 50,000 people globally, with prevalence estimates ranging from 1:10,000 to 1:150,000. The increasing prevalence of HAE is driving the demand for takhzyro.

The growth of the takhzyro market is also being fueled by rising healthcare expenditure. This refers to the total financial resources spent on health services and related activities over a specific period, typically measured annually. The increase in healthcare spending is driven by factors such as an aging population, chronic diseases, rising service prices, higher demand, technological advancements, increasing drug costs, the impact of COVID-19, medical inflation, and income disparities. As healthcare expenditure rises, there is growing demand for effective treatments such as takhzyro, which influences market pricing and cost-effectiveness assessments. For example, in November 2024, Eurostat reported that Germany led the EU in healthcare expenditure in 2022, allocating approximately $520 billion, followed by France with $340 billion, Italy with $190 billion, and Spain with $140 billion. These increases reflect a year-over-year growth compared to 2021, when the expenditures were lower.

A key trend in the takhzyro market is the focus on developing advanced pediatric prophylaxis treatments for preventing hereditary angioedema (HAE) attacks in both adult and pediatric patients aged 12 and older. Prophylaxis refers to preventive measures taken to avoid disease or infection, including medications or vaccinations. In February 2023, Takeda Pharmaceutical Company announced that the U.S. Food and Drug Administration (FDA) approved the supplemental biologics license application (sBLA) for the expanded use of TAKHZYRO (lanadelumab-flyo) to prevent HAE attacks in pediatric patients aged 2 to under 12 years. This approval was supported by efficacy data from the HELP Study, a Phase 3 trial involving patients aged 12 to under 18.

The key company operating in the takhzyro market is Takeda Pharmaceuticals Inc.

North America was the largest region in the takhzyro market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in takhzyro report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the takhzyro market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Takhzyro (lanadelumab-flyo) is a prescription medication used to prevent attacks of hereditary angioedema (HAE) in individuals aged 2 years and older. It is a monoclonal antibody that works by inhibiting plasma kallikrein, which reduces bradykinin levels and consequently lowers the frequency and severity of swelling episodes associated with HAE.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for Takhzyro include hereditary angioedema (HAE) prophylaxis, treatment of acute HAE attacks, and other related indications. HAE prophylaxis refers to preventive treatment that aims to decrease the frequency and severity of angioedema attacks in individuals with HAE. The medication is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by a wide range of end users, including pediatric, adult, and geriatric patients.

The takhzyro market consists of sales of single-dose prefilled syringes, single-dose vials, and ready-to-use solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.